^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1361849

    i
    Other names: BI 1361849, CV-9202, CV9202, CV 9202
    Associations

    News

    Trials
    Company:
    CureVac
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    mRNA Vaccines in Modern Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)-A Comprehensive Literature Review with Focus on Current Clinical Trials. (PubMed, Biomedicines)
    Completed clinical trials have assessed the safety and potential benefit of selected mRNA vaccines-such as CV9202-administered alone or in combination with radiotherapy or tyrosine kinase inhibitors...However, larger and long-term studies are required to fully confirm their safety and efficacy. Future research should aim to identify the most effective antigens, enhance stability, and refine delivery strategies to improve efficacy and personalization, while also addressing immune suppression within the tumor microenvironment.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    BI 1361849
    4years
    Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
    P1/2, N=59, Completed, Ludwig Institute for Cancer Research | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2021
    Clinical • Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849
    almost5years
    Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Ludwig Institute for Cancer Research | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Oct 2021
    Clinical • Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849 • self-amplifying RNA cancer vaccine
    over5years
    Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. (PubMed, J Immunother Cancer)
    The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
    Clinical • P1 data • Journal
    |
    MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    EGFR mutation
    |
    pemetrexed • BI 1361849